BLS Pharmaceuticals (PR80) Stock Overview
Manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PR80 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
BLS Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.51 |
| 52 Week High | AU$0.88 |
| 52 Week Low | AU$0.01 |
| Beta | 0.65 |
| 1 Month Change | 26.25% |
| 3 Month Change | 29.49% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 68.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| PR80 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.5% | -7.7% | 0.5% |
| 1Y | n/a | -2.5% | -0.9% |
Return vs Industry: Insufficient data to determine how PR80 performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how PR80 performed against the German Market.
Price Volatility
| PR80 volatility | |
|---|---|
| PR80 Average Weekly Movement | 177.9% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: PR80's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PR80's weekly volatility has increased from 149% to 178% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Sam Watson | blspharma.com |
BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines.
BLS Pharmaceuticals Limited Fundamentals Summary
| PR80 fundamental statistics | |
|---|---|
| Market cap | €118.60m |
| Earnings (TTM) | €5.48m |
| Revenue (TTM) | €29.44m |
Is PR80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PR80 income statement (TTM) | |
|---|---|
| Revenue | AU$47.95m |
| Cost of Revenue | AU$28.27m |
| Gross Profit | AU$19.69m |
| Other Expenses | AU$10.77m |
| Earnings | AU$8.92m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.039 |
| Gross Margin | 41.05% |
| Net Profit Margin | 18.60% |
| Debt/Equity Ratio | 13.6% |
How did PR80 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/24 09:01 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BLS Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.